Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma

Anti-Cancer Drugs

Volumn 23, Issue 9, 2012, Pages 996-1001

  Péron, Julien ^a   Ceruse, Philippe ^d   Lavergne, Emilie ^b   Buiret, Guillaume ^d   Pham, Bich Nga ^d   Chabaud, Sylvie ^b   Favier, Bertrand ^a   Girodet, Didier ^c   Zrounba, Philippe ^c   Ramade, Antoine ^e   Fayette, Jérôme ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Department of Biostatistics ^*  (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

cetuximab; chemotherapy; paclitaxel; recurrent metastatic head and neck squamous cell carcinoma; survival

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DOCETAXEL; FLUOROURACIL; METOCLOPRAMIDE; ONDANSETRON; PACLITAXEL; PLATINUM; RANITIDINE; TAXANE DERIVATIVE;

ADULT; AGED; APLASIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE APLASIA; FEMALE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INFECTION; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84866000699     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835507e5     Document Type: Article

References (29)

1. IARC. Cancer mondial: GLOBOCAN; 2010. Available at: www-dep.iarc.fr [Accessed 21 May 2012].
2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127.
3. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715.
4. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695-1704.
5. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992; 10:1245-1251.
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
7. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
8. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinumbased therapies. Cancer 2008; 112:2710-2719.
9. Baur M, Kienzer HR, Schweiger J, DeSantis M, Gerber E, Pont J, et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: A phase II trial. Cancer 2002; 94:2953-2958.
10. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
11. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial ofdocetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20:1593-1599.
12. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11:845-849.
13. Molin Y, Fayette J. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs 2010; 22:621-625.
14. Fayette J, Montella A, Chabaud S, Bachelot T, Pommier P, Girodet D, et al. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: A retrospective study of 66 patients at a single institution. Anticancer Drugs 2010; 21:553-558.
15. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40:2071-2076.
16. Kies MS, Holsinger FC, Lee JJ, William WN Jr., Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cellcarcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2009; 28:8-14.
17. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garcia-Saenz JA, Cruz- Hernandez JJ. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23:1016-1022.
18. Jimenez B, Trigo Perez M, Saez Medina MI, Quero Blanco C, Pajares B, Rueda A, et al. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients [abstract]. J Clin Oncol 2011; 29:5594.
19. Grau JJ, Caballero M, Monzo M, Munoz-Garcia C, Domingo-Domenech J, Navarro A, et al. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 2008; 98:130-134.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
21. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
22. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
23. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654.
24. Vermorken JB, Stöhlmacher J, Davidenko I, Licitra L,Winquist E, Skladowski K, et al. Primary efficacy and safety results of spectrum, a phase 3 trial in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without panitumumab. 35th ESMO congress 2010; Milan; LBA 26.
25. Rose WC,Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res 2004; 10:7413-7417.
26. Guigay J, Fayette J, Dillies A, Sire C, Kerger JN, Tennevet I, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first results of phase II trial GORTEC 2008-03 [abstract]. J Clin Oncol 2011; 29:5567.
27. Knoedler MK, Gauler T, Matzdorff A, Jordan O, Schroeder M, Gruenwald V, et al. Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN (abstract). J Clin Oncol (ASCO meeting) 2009; 6048.
28. Sparano JA,Wang M, Martino S, Jones V, Perez EA, Saphner T, et al.Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663-1671.
29. Leó n X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 418-424.